SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Angela Pappalardo, Keith Thompson, Novel immunostimulatory effects of osteoclasts and macrophages on human γδ T cells, Bone, 2015, 71, 180

    CrossRef

  2. 2
    Simon Junankar, Michael J. Rogers, Bone Cancer, 2015,

    CrossRef

  3. 3
    Silvina Andrea Soto, Angelina Chiappe Barbará, Bisphosphonates: Pharmacology and Clinical Approach to Their Use in Equine Osteoarticular Diseases, Journal of Equine Veterinary Science, 2014, 34, 6, 727

    CrossRef

  4. 4
    Helen F. Galley, Damon A. Lowes, Keith Thompson, Naomi D. Wilson, Carol A. Wallace, Nigel R. Webster, Characterisation of gamma delta (γδ) T cell populations in patients with sepsis, Cell Biology International, 2014, 38, 12
  5. 5
    T. Sree Latha, Madhava C. Reddy, Prasad V. R. Durbaka, Aparna Rachamallu, Reddanna Pallu, Dakshayani Lomada, γδ T Cell-Mediated Immune Responses in Disease and Therapy, Frontiers in Immunology, 2014, 5,

    CrossRef

  6. 6
    Nadine Hagelauer, Andreas Max Pabst, Thomas Ziebart, Holger Ulbrich, Christian Walter, In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes, Clinical Oral Investigations, 2014,

    CrossRef

  7. 7
    David F. Wiemer, Andrew J. Wiemer, Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists, Biochemical Pharmacology, 2014, 89, 3, 301

    CrossRef

  8. 8
    Emilie Decaup, Caroline Duault, Christine Bezombes, Mary Poupot, Ariel Savina, Daniel Olive, Jean-Jacques Fournié, Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes, Immunology Letters, 2014, 161, 1, 133

    CrossRef

  9. 9
    Chia-Hung Christine Hsiao, Xiaochen Lin, Rocky J. Barney, Rebekah R. Shippy, Jin Li, Olga Vinogradova, David F. Wiemer, Andrew J. Wiemer, Synthesis of a Phosphoantigen Prodrug that Potently Activates Vγ9Vδ2 T-Lymphocytes, Chemistry & Biology, 2014, 21, 8, 945

    CrossRef

  10. 10
    Atif S. M. Idrees, Tomoharu Sugie, Chiyomi Inoue, Kaoru Murata-Hirai, Haruki Okamura, Craig T. Morita, Nagahiro Minato, Masakazu Toi, Yoshimasa Tanaka, Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid, Cancer Science, 2013, 104, 5
  11. 11
    Shirin Kalyan, Dieter Kabelitz, Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic, Cellular and Molecular Immunology, 2013, 10, 1, 21

    CrossRef

  12. 12
    B. Torger, M. Müller, In situ-ATR–FTIR analysis on the uptake and release of streptomycin from polyelectrolyte complex layers, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2013, 104, 546

    CrossRef

  13. 13
    Patricia Sieber, Patrizia Lardelli, Claude A. Kraenzlin, Marius E. Kraenzlin, Christian Meier, Intravenous Bisphosphonates for Postmenopausal Osteoporosis: Safety Profiles of Zoledronic Acid and Ibandronate in Clinical Practice, Clinical Drug Investigation, 2013, 33, 2, 117

    CrossRef

  14. 14
    Jean-Jacques Fournié, Hélène Sicard, Mary Poupot, Christine Bezombes, Amandine Blanc, François Romagné, Loic Ysebaert, Guy Laurent, What lessons can be learned from γδ T cell-based cancer immunotherapy trials?, Cellular and Molecular Immunology, 2013, 10, 1, 35

    CrossRef

  15. You have free access to this content15
    Pascale Schwab, David Harmon, Richard Bruno, Frederick W. Fraunfelder, Donna Hyunchung Kim, A 55-year-old woman with orbital inflammation, Arthritis Care & Research, 2012, 64, 11
  16. 16
    Mudumala Veera Narayana Reddy, Jongsik Kim, Yeon Tae Jeong, A facile synthesis of aminomethylene bisphosphonates catalyzed by ytterbium perfluorooctanoate under ionic liquid condition, Journal of Fluorine Chemistry, 2012, 135, 155

    CrossRef

  17. 17
    Athanasios D. Anastasilakis, Stergios A. Polyzos, Polyzois Makras, Grigorios T. Sakellariou, Ilias Bisbinas, Athina Gkiomisi, Sideris Delaroudis, Spyridon Gerou, Iris Ballaouri, Dimitrios Oikonomou, Socrates E. Papapoulos, Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass, Bone, 2012, 50, 5, 1130

    CrossRef

  18. 18
    Maurizio Rossini, Silvano Adami, Ombretta Viapiana, Riccardo Ortolani, Antonio Vella, Elena Fracassi, Davide Gatti, Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration, Journal of Bone and Mineral Research, 2012, 27, 1
  19. 19
    J.-J. Body, P. Bergmann, S. Boonen, J.-P. Devogelaer, E. Gielen, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster, Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications, Osteoporosis International, 2012, 23, S1, 1

    CrossRef

  20. 20
    Maurizio Rossini, Silvano Adami, Ombretta Viapiana, Elena Fracassi, Riccardo Ortolani, Antonio Vella, Roberta Zanotti, Gaia Tripi, Luca Idolazzi, Davide Gatti, Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells, Calcified Tissue International, 2012, 91, 6, 395

    CrossRef

  21. 21
    Pui Yan Jenny Chung, Wim Van Hul, Paget's Disease of Bone: Evidence for Complex Pathogenetic Interactions, Seminars in Arthritis and Rheumatism, 2012, 41, 5, 619

    CrossRef

  22. 22
    Catalina Orozco, Naim M. Maalouf, Safety of Bisphosphonates, Rheumatic Disease Clinics of North America, 2012, 38, 4, 681

    CrossRef

  23. 23
    Antonino Catalano, Nancy Morabito, Marco Atteritano, Giorgio Basile, Domenico Cucinotta, Antonino Lasco, Vitamin D Reduces Musculoskeletal Pain After Infusion of Zoledronic Acid for Postmenopausal Osteoporosis, Calcified Tissue International, 2012, 90, 4, 279

    CrossRef

  24. 24
    John J. Freiberger, Rebecca Padilla-Burgos, Thomas McGraw, Hagir B. Suliman, Kevin H. Kraft, Bryant W. Stolp, Richard E. Moon, Claude A. Piantadosi, What Is the Role of Hyperbaric Oxygen in the Management of Bisphosphonate-Related Osteonecrosis of the Jaw: A Randomized Controlled Trial of Hyperbaric Oxygen as an Adjunct to Surgery and Antibiotics, Journal of Oral and Maxillofacial Surgery, 2012, 70, 7, 1573

    CrossRef

  25. 25
    René Rizzoli, Jean-Yves Reginster, Adverse drug reactions to osteoporosis treatments, Expert Review of Clinical Pharmacology, 2011, 4, 5, 593

    CrossRef

  26. 26
    René Rizzoli, Jean-Yves Reginster, Steven Boonen, Gérard Bréart, Adolfo Diez-Perez, Dieter Felsenberg, Jean-Marc Kaufman, John A. Kanis, Cyrus Cooper, Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis, Calcified Tissue International, 2011, 89, 2, 91

    CrossRef

  27. 27
    Michael J. Rogers, Julie C. Crockett, Fraser P. Coxon, Jukka Mönkkönen, Biochemical and molecular mechanisms of action of bisphosphonates, Bone, 2011, 49, 1, 34

    CrossRef

  28. 28
    R. Rizzoli, Bisphosphonates for post-menopausal osteoporosis: are they all the same?, QJM, 2011, 104, 4, 281

    CrossRef

  29. 29
    R. Graham G. Russell, Bisphosphonates: The first 40years, Bone, 2011, 49, 1, 2

    CrossRef

  30. 30
    Roland Baron, Serge Ferrari, R. Graham G. Russell, Denosumab and bisphosphonates: Different mechanisms of action and effects, Bone, 2011, 48, 4, 677

    CrossRef

  31. 31
    S. L. Silverman, A. Kriegman, J. Goncalves, F. Kianifard, T. Carlson, E. Leary, Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid, Osteoporosis International, 2011, 22, 8, 2337

    CrossRef

  32. 32
    Keith Thompson, Fran Keech, David J. McLernon, Kumar Vinod, Robin J. May, William G. Simpson, Michael J. Rogers, David M. Reid, Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women, Bone, 2011, 49, 1, 140

    CrossRef

  33. 33
    Polyzois Makras, Athanasios D. Anastasilakis, Stergios A. Polyzos, Ilias Bisbinas, Grigorios T. Sakellariou, Socrates E. Papapoulos, No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response, Calcified Tissue International, 2011, 88, 5, 402

    CrossRef

  34. 34
    Benoit Le Goff, Dominique Heymann, Pharmacodynamics of bisphosphonates in arthritis, Expert Review of Clinical Pharmacology, 2011, 4, 5, 633

    CrossRef

  35. 35
    Regina Landesberg, Victoria Woo, Serge Cremers, Matthew Cozin, Darja Marolt, Gordana Vunjak-Novakovic, Stavroula Kousteni, Srikala Raghavan, Potential pathophysiological mechanisms in osteonecrosis of the jaw, Annals of the New York Academy of Sciences, 2011, 1218, 1
  36. 36
    Tarak Srivastava, Hongying Dai, Connie J Haney, Uri S Alon, Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate, Journal of Bone and Mineral Research, 2011, 26, 2
  37. 37
    Barbara Castella, Candida Vitale, Marta Coscia, Massimo Massaia, Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside, Cellular and Molecular Life Sciences, 2011, 68, 14, 2419

    CrossRef

  38. 38
    Sarah A. Holstein, Raymond J. Hohl, Protein Prenylation Part B, 2011,

    CrossRef

  39. 39
    Julie M. Jameson, John Cruz, Anne Costanzo, Masanori Terajima, Francis A. Ennis, A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human γδ T lymphocytes, Cellular Immunology, 2010, 264, 1, 71

    CrossRef

  40. 40
    Bo Abrahamsen, Adverse Effects of Bisphosphonates, Calcified Tissue International, 2010, 86, 6, 421

    CrossRef

  41. 41
    P. D’Amelio, A. Grimaldi, M. A. Cristofaro, M. Ravazzoli, P. A. Molinatti, G. P. Pescarmona, G. C. Isaia, Alendronate reduces osteoclast precursors in osteoporosis, Osteoporosis International, 2010, 21, 10, 1741

    CrossRef

  42. 42
    Jonathan Green, Allan Lipton, Anticancer Properties of Zoledronic Acid, Cancer Investigation, 2010, 28, 9, 944

    CrossRef

  43. 43
    G. R. Werner de Castro, F. S. Neves, S. C. de Magalhães Souza Fialho, I. A. Pereira, G. Ribeiro, A. F. Zimmermann, Flare-up of hand osteoarthritis caused by zoledronic acid infusion, Osteoporosis International, 2010, 21, 9, 1617

    CrossRef

  44. 44
    Anke J Roelofs, Fraser P Coxon, Frank H Ebetino, Mark W Lundy, Zachary J Henneman, George H Nancollas, Shuting Sun, Katarzyna M Blazewska, Joy Lynn F Bala, Boris A Kashemirov, Aysha B Khalid, Charles E McKenna, Michael J Rogers, Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo, Journal of Bone and Mineral Research, 2010, 25, 3
  45. 45
    Michael W. Traxlmayr, Daniela Wesch, Alexander M. Dohnal, Philipp Funovics, Michael B. Fischer, Dieter Kabelitz, Thomas Felzmann, Immune Suppression by γδ T-cells as a Potential Regulatory Mechanism After Cancer Vaccination With IL-12 Secreting Dendritic Cells, Journal of Immunotherapy, 2010, 33, 1, 40

    CrossRef

  46. 46
    Takefumi Oizumi, Hiromi Funayama, Kouji Yamaguchi, Masayoshi Yokoyama, Harue Takahashi, Miou Yamamoto, Toshinobu Kuroishi, Hiroyuki Kumamoto, Keiichi Sasaki, Hiroshi Kawamura, Shunji Sugawara, Yasuo Endo, Inhibition of Necrotic Actions of Nitrogen-Containing Bisphosphonates (NBPs) and Their Elimination From Bone by Etidronate (a Non-NBP): A Proposal for Possible Utilization of Etidronate as a Substitution Drug for NBPs, Journal of Oral and Maxillofacial Surgery, 2010, 68, 5, 1043

    CrossRef

  47. 47
    Yonghui Zhang, Rong Cao, Fenglin Yin, Fu-Yang Lin, Hong Wang, Kilannin Krysiak, Joo-Hwan No, Dushyant Mukkamala, Kevin Houlihan, Jikun Li, Craig T. Morita, Eric Oldfield, Lipophilic Pyridinium Bisphosphonates: Potent γδ T Cell Stimulators, Angewandte Chemie International Edition, 2010, 49, 6
  48. 48
    Yonghui Zhang, Rong Cao, Fenglin Yin, Fu-Yang Lin, Hong Wang, Kilannin Krysiak, Joo-Hwan No, Dushyant Mukkamala, Kevin Houlihan, Jikun Li, Craig T. Morita, Eric Oldfield, Lipophilic Pyridinium Bisphosphonates: Potent γδ T Cell Stimulators, Angewandte Chemie, 2010, 122, 6
  49. 49
    Ismahène Benzaid, Philippe Clézardin, Nitrogen-containing bisphosphonates and human γδ T cells, IBMS BoneKEy, 2010, 7, 6, 208

    CrossRef

  50. 50
    Kouji Yamaguchi, Takefumi Oizumi, Hiromi Funayama, Hiroshi Kawamura, Shunji Sugawara, Yasuo Endo, Osteonecrosis of the Jawbones in 2 Osteoporosis Patients Treated With Nitrogen-Containing Bisphosphonates: Osteonecrosis Reduction Replacing NBP With Non-NBP (Etidronate) and Rationale, Journal of Oral and Maxillofacial Surgery, 2010, 68, 4, 889

    CrossRef

  51. 51
    Oya Umit Yemisci, Seniz Akcay Yalbuzdag, Metin Karatas, Risedronate-Induced Arthritis, JCR: Journal of Clinical Rheumatology, 2010, 16, 4, 168

    CrossRef

  52. 52
    Francesco Bertoldo, Serena Pancheri, Sonia Zenari, Stefania Boldini, Benedetta Giovanazzi, Mirko Zanatta, Maria Teresa Valenti, Luca Dalle Carbonare, Vincenzo Lo Cascio, Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion, Journal of Bone and Mineral Research, 2010, 25, 3
  53. 53
    Andreas Guenther, Sharon Gordon, Markus Tiemann, Renate Burger, Frank Bakker, Jonathan R. Green, Wolfgang Baum, Anke J. Roelofs, Michael J. Rogers, Martin Gramatzki, The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation, International Journal of Cancer, 2010, 126, 1
  54. 54
    David M. Reid, Update on the Use of Zoledronic Acid in the Management of Osteoporosis, Current Osteoporosis Reports, 2010, 8, 3, 145

    CrossRef

  55. You have free access to this content55
    TE Sondergaard, PT Pedersen, TL Andersen, K Søe, T Lund, B Østergaard, P Garnero, J-M Delaisse, T Plesner, A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma, Hematological Oncology, 2009, 27, 1
  56. 56
    Xue Deng, Riyoko Tamai, Yasuo Endo, Yusuke Kiyoura, Alendronate augments interleukin-1β release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1, Toxicology and Applied Pharmacology, 2009, 235, 1, 97

    CrossRef

  57. 57
    J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, L. Ysebaert, G. Laurent, H. Sicard, J.-J. Fournie, Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies, Blood, 2009, 113, 20, 4875

    CrossRef

  58. 58
    Daniele Santini, Federico Martini, Maria Elisabetta Fratto, Sara Galluzzo, Bruno Vincenzi, Chiara Agrati, Federica Turchi, Paola Piacentini, Laura Rocci, John S. Manavalan, Giuseppe Tonini, Fabrizio Poccia, In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients, Cancer Immunology, Immunotherapy, 2009, 58, 1, 31

    CrossRef

  59. 59
    Anke J. Roelofs, Marjo Jauhiainen, Hannu Mönkkönen, Michael J. Rogers, Jukka Mönkkönen, Keith Thompson, Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP, British Journal of Haematology, 2009, 144, 2
  60. 60
    Kia Joo Puan, John Seng Hooi Low, Terence Wee Kiat Tan, Joseph Tien Seng Wee, Eng Huat Tan, Kam Weng Fong, Eu Tiong Chua, Chenggang Jin, José-Luis Giner, Craig T. Morita, Christopher Hood Keng Goh, Kam M. Hui, Phenotypic and functional alterations of Vγ2Vδ2 T cell subsets in patients with active nasopharyngeal carcinoma, Cancer Immunology, Immunotherapy, 2009, 58, 7, 1095

    CrossRef

  61. 61
    Yosuke Shima, Lars Engebretsen, Junji Iwasa, Katsuhiko Kitaoka, Katsuro Tomita, Use of bisphosphonates for the treatment of stress fractures in athletes, Knee Surgery, Sports Traumatology, Arthroscopy, 2009, 17, 5, 542

    CrossRef

  62. 62
    Fabrizio Poccia, Cristiana Gioia, Federico Martini, Alessandra Sacchi, Paola Piacentini, Massimo Tempestilli, Chiara Agrati, Alessandra Amendola, Amina Abdeddaim, Chrysoula Vlassi, Miroslav Malkovsky, Gianpiero DʼOffizi, Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vγ9Vδ2 T cells, AIDS, 2009, 23, 5, 555

    CrossRef

  63. 63
    Anna Gajda, Tadeusz Gajda, A new access to substituted tetraethyl N-Boc 2-aminoethylidene-1,1-bisphosphonates and phosphonyl-substituted aza-Morita–Baylis–Hillman-type adducts, Tetrahedron, 2008, 64, 7, 1233

    CrossRef

  64. 64
    Fraser P Coxon, An update on the pharmacology of bisphosphonates and analogues with lower bone affinity, IBMS BoneKEy, 2008, 5, 10, 357

    CrossRef

  65. 65
    R. G. G. Russell, N. B. Watts, F. H. Ebetino, M. J. Rogers, Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy, Osteoporosis International, 2008, 19, 6, 733

    CrossRef

  66. 66
    Xin Li, Laurie K McCauley, Osteonecrosis of the jaw: Meeting report from skeletal complications of malignancy V, IBMS BoneKEy, 2008, 5, 8, 289

    CrossRef

  67. 67
    Patrizia D'Amelio, Anastasia Grimaldi, Stefania Di Bella, Cristina Tamone, Stefano ZM Brianza, Marco GA Ravazzoli, Paola Bernabei, Maria Angela Cristofaro, Gian Piero Pescarmona, Giancarlo Isaia, Risedronate Reduces Osteoclast Precursors and Cytokine Production in Postmenopausal Osteoporotic Women, Journal of Bone and Mineral Research, 2008, 23, 3
  68. 68
    Sohita Dhillon, Katherine A Lyseng-Williamson, Zoledronic Acid, Drugs, 2008, 68, 4, 507

    CrossRef

  69. 69
    Christof Nolde, Markus Schürmann, Michael Mehring, A Sterically Hindered Phosphonic Acid with a Hydrogen-Bonded Cage Structure: [4-tert-Bu-2,6-Mes2-C6H2P(O)(OH)2·H2O]4, Zeitschrift für anorganische und allgemeine Chemie, 2007, 633, 1
  70. 70
    Aaron Schindeler, David G. Little, Bisphosphonate action: Revelations and deceptions from in vitro studies, Journal of Pharmaceutical Sciences, 2007, 96, 8
  71. 71
    Melinda A. Merrell, Savita Wakchoure, Joanna M. Ilvesaro, Kurt Zinn, Bradley Gehrs, Petri P. Lehenkari, Kevin W. Harris, Katri S. Selander, Differential effects of Ca2+ on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells, European Journal of Pharmacology, 2007, 559, 1, 21

    CrossRef

  72. 72
    Xue Deng, Zhiqian Yu, Hiromi Funayama, Kouji Yamaguchi, Takashi Sasano, Shunji Sugawara, Yasuo Endo, Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells, International Immunopharmacology, 2007, 7, 2, 152

    CrossRef

  73. 73
    Susann Beetz, Lothar Marischen, Dieter Kabelitz, Daniela Wesch, Human γδ T cells, Immunologic Research, 2007, 37, 2, 97

    CrossRef

  74. 74
    S Galluzzo, D Santini, B Vincenzi, N Caccamo, F Meraviglia, A Salerno, F Dieli, G Tonini, Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity, Expert Opinion on Therapeutic Targets, 2007, 11, 7, 941

    CrossRef

  75. 75
    Melinda A. Merrell, Savita Wakchoure, Petri P. Lehenkari, Kevin W. Harris, Katri S. Selander, Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells, European Journal of Pharmacology, 2007, 570, 1-3, 27

    CrossRef

  76. 76
    Craig T. Morita, Chenggang Jin, Ghanashyam Sarikonda, Hong Wang, Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens, Immunological Reviews, 2007, 215, 1
  77. 77
    William Strampel, Ronald Emkey, Roberto Civitelli, Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis, Drug Safety, 2007, 30, 9, 755

    CrossRef

  78. 78
    Keith Thompson, Michael J. Rogers, The Molecular Mechanisms of Action of Bisphosphonates, Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 3, 130

    CrossRef

  79. 79
    Colin R Dunstan, Dieter Felsenberg, Markus J Seibel, Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease, Nature Clinical Practice Oncology, 2007, 4, 1, 42

    CrossRef

  80. 80
    David Hosking, Zoledronic acid in Paget’s disease, Therapy, 2007, 4, 4, 391

    CrossRef

  81. 81
    Keith Thompson, Michael J Rogers, Bisphosphonates and γδ t-cells: New insights into old drugs, BoneKEy-Osteovision, 2006, 3, 8, 5

    CrossRef

  82. 82
    Franco Pernice, Fulvio Floccari, Chiara Caccamo, Nadia Belghity, Stefania Mantuano, Maria Elisa Pacilè, Adolfo Romeo, Lorena Nostro, Antonio Barillà, Eleonora Crascì, Nicola Frisina, Michele Buemi, Chromosomal damage and atherosclerosis. A protective effect from simvastatin, European Journal of Pharmacology, 2006, 532, 3, 223

    CrossRef

  83. 83
    Francesco Dieli, Nadia Caccamo, Immunomodulatory role of statins in autoimmune disease: is there a role for human γδT cells?, Nature Reviews Immunology, 2006, 6, 7

    CrossRef

  84. 84
    Xue Deng, Zhiqian Yu, Hiromi Funayama, Noriaki Shoji, Takashi Sasano, Yoichiro Iwakura, Shunji Sugawara, Yasuo Endo, Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate, Toxicology and Applied Pharmacology, 2006, 213, 1, 64

    CrossRef

  85. 85
    Pierrick GJ Fournier, John M Chirgwin, Theresa A Guise, New insights into the role of T cells in the vicious cycle of bone metastases, Current Opinion in Rheumatology, 2006, 18, 4, 396

    CrossRef

  86. 86
    Jean-Pierre Devogelaer, Christine Coppin, Osteogenesis Imperfecta, Treatments in Endocrinology, 2006, 5, 4, 229

    CrossRef

  87. 87
    Christian Belmant, Donatella Decise, Jean-Jacques Fournié, Phosphoantigens and aminobisphosphonates: New leads targeting γδ T lymphocytes for cancer immunotherapy, Drug Discovery Today: Therapeutic Strategies, 2006, 3, 1, 17

    CrossRef

  88. 88
    Willi K Born, Christopher L Reardon, Rebecca L O’Brien, The function of γδ T cells in innate immunity, Current Opinion in Immunology, 2006, 18, 1, 31

    CrossRef

  89. 89
    Jack F. Bukowski, Christopher C. Dascher, Hiranmoy Das, Alternative bisphosphonate targets and mechanisms of action, Biochemical and Biophysical Research Communications, 2005, 328, 3, 746

    CrossRef

  90. 90
    Zhiqian Yu, Hiromi Funayama, Xue Deng, Toshinobu Kuroishi, Takashi Sasano, Shunji Sugawara, Yasuo Endo, Comparative Appraisal of Clodronate, Aspirin and Dexamethasone as Agents Reducing Alendronate-induced Inflammation in a Murine Model, Basic & Clinical Pharmacology & Toxicology, 2005, 97, 4
  91. 91
    Kiyoshi Sato, Shinya Kimura, Hidekazu Segawa, Asumi Yokota, Seiji Matsumoto, Junya Kuroda, Masaki Nogawa, Takeshi Yuasa, Yasushi Kiyono, Hiromi Wada, Taira Maekawa, Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy, International Journal of Cancer, 2005, 116, 1
  92. 92
    S Mariani, M Muraro, F Pantaleoni, F Fiore, B Nuschak, S Peola, M Foglietta, A Palumbo, M Coscia, B Castella, B Bruno, R Bertieri, L Boano, M Boccadoro, M Massaia, Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma, Leukemia, 2005,

    CrossRef

  93. 93
    Marc Bonneville, Jean-Jacques Fournié, Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites, Microbes and Infection, 2005, 7, 3, 503

    CrossRef

  94. 94
    R. E. Hewitt, A. Lissina, A. E. Green, E. S. Slay, D. A. Price, A. K. Sewell, The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins, Clinical & Experimental Immunology, 2005, 139, 1
  95. 95
    Mary Poupot, Jean-Jacques Fournié, Non-peptide antigens activating human Vγ9/Vδ2 T lymphocytes, Immunology Letters, 2004, 95, 2, 129

    CrossRef

  96. 96
    Joseph R Tucci, Paget disease of bone, Current Opinion in Endocrinology & Diabetes, 2004, 11, 6, 321

    CrossRef